Article
Microbiology
Jacqueline Findlay, Laurent Poirel, Mario Juhas, Patrice Nordmann
Summary: This study evaluated the impact of KPC variants on CZA resistance, finding increased susceptibility to cephalosporins and carbapenems but increased resistance to ceftazidime and piperacillin-tazobactam. The KPC variants exhibited increased affinity towards ceftazidime and slightly decreased sensitivity to avibactam, impacting CZA resistance while concurrently negatively impacting carbapenemase activities.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2021)
Article
Infectious Diseases
Laura Campogiani, Pietro Vitale, Alessandra Lodi, Alessandra Imeneo, Carla Fontana, Cartesio D'Agostini, Mirko Compagno, Luigi Coppola, Ilaria Spalliera, Vincenzo Malagnino, Elisabetta Teti, Marco Iannetta, Massimo Andreoni, Loredana Sarmati
Summary: This study aimed to collect and describe real-life data on CAZ-AVI-resistant Klebsiella pneumoniae isolates in a University Hospital. The results showed that prior use of CAZ-AVI was associated with the emergence of drug resistance.
Article
Microbiology
Xiangning Huang, Siquan Shen, Fan Chang, Xin Liu, Jinxi Yue, Ning Xie, Lin Yin, Fupin Hu, Daiwen Xiao
Summary: The emergence of new KPC variants leading to treatment failure with ceftazidime-avibactam presents a new challenge for clinical anti-infection treatment. In this study, a ceftazidime-avibactam-resistant K. pneumoniae strain carrying a novel KPC-134 variant was reported. The study highlights the importance of timely identification of KPC variants and effective anti-infective therapy for saving infected patients.
MICROBIOLOGY SPECTRUM
(2023)
Article
Immunology
Yili Chen, Runshi Yang, Penghao Guo, Pingjuan Liu, Jiankai Deng, Zhongwen Wu, Qingping Wu, Junqi Huang, Kang Liao
Summary: This study reports the first case of CZA resistance caused by bla(KPC-145) emerging during treatment of K. pneumoniae infection associated with bla(KPC-2) in China. Routine testing for antibiotic susceptibility and carbapenemase genotype is essential during CZA treatment.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2023)
Article
Microbiology
Yanqin Huang, Tiffany Wu, Omar Perez, Amisha P. Rana, Liang Chen, Barry N. Kreiswirth, Michael J. Satlin, Zackery P. Bulman
Summary: Ceftazidime/avibactam is an important treatment option for infections caused by KPC-Kp, but resistance can emerge during treatment. The study aimed to define the concentrations required to suppress regrowth in ceftazidime/avibactam susceptible isolates and identify active therapies against ceftazidime/avibactam-resistant KPC-Kp.
FRONTIERS IN MICROBIOLOGY
(2021)
Article
Microbiology
Alessandra Carattoli, Gabriele Arcari, Giulia Bibbolino, Federica Sacco, Dario Tomolillo, Federica Maria Di Lella, Maria Trancassini, Luigi Faino, Mario Venditti, Guido Antonelli, Giammarco Raponi
Summary: A study conducted in a university hospital in Rome, Italy identified multiple CZA-resistant KPC-3 protein variants, including novel variants that had not been reported before. These variants showed different sensitivities and activities to antibiotics, possibly due to mutations caused by amino acid substitutions, insertions, and deletions.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2021)
Article
Infectious Diseases
Isabel Machuca, Julia Guzman-Puche, E. Perez-Nadales, I Gracia-Ahufinger, A. Mendez, A. Cano, J. J. Caston, A. Dominguez, J. Torre-Cisneros, L. Martinez-Martinez
Summary: This study describes the clinical and microbiological features of a community-acquired infection caused by KPC-producing K. pneumoniae resistant to ceftazidime/avibactam. The bacteria isolates were resistant to carbapenems and ceftazidime/avibactam, but susceptible to trimethoprim-sulfamethoxazole. Whole genome sequencing revealed genetic differences and the presence of a plasmid associated with trimethoprim-sulfamethoxazole resistance.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE
(2022)
Article
Infectious Diseases
Matteo Boattini, Gabriele Bianco, Paulo Bastos, Sara Comini, Silvia Corcione, Andre Almeida, Cristina Costa, Francesco Giuseppe De Rosa, Rossana Cavallo
Summary: This study aimed to identify risk factors for mortality in patients with ceftazidime/avibactam-resistant KPC-Kp bloodstream infection. The study found that ceftazidime/avibactam resistance in KPC-Kp BSI easily emerged in highly endemic areas, with significant mortality rates.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
(2023)
Article
Microbiology
Xiangning Huang, Siquan Shen, Fan Chang, Xin Liu, Jinxi Yue, Ning Xie, Lin Yin, Fupin Hu, Daiwen Xiao
Summary: This study reports a ceftazidime-avibactam-resistant Klebsiella pneumoniae strain carrying a novel KPC variant, KPC-134. The isolate showed resistance to multiple antibiotics but sensitivity to certain others. Further experiments revealed that the resistance was primarily mediated by a plasmid carrying the bla(KPC-134) gene, which also harbored other common resistance genes.
MICROBIOLOGY SPECTRUM
(2023)
Article
Microbiology
Chunlei Wang, Jiankang Zhao, Zhibo Liu, Aihua Sun, Lingxiao Sun, Binbin Li, Binghuai Lu, Yingmei Liu, Bin Cao
Summary: This study describes the in vivo evolution of carbapenem and ceftazidime-avibactam resistance in a pneumonia patient by analyzing four longitudinal Klebsiella pneumoniae clinical isolates. The results showed a dynamic change of resistance phenotype and the emergence of resistance to ceftazidime-avibactam and carbapenems.
FRONTIERS IN MICROBIOLOGY
(2021)
Article
Infectious Diseases
Carolina Venditti, Ornella Butera, Marcello Meledandri, Maria Pia Balice, Giulio Cesare Cocciolillo, Carla Fontana, Silvia D'Arezzo, Chiara De Giuli, Mario Antonini, Alessandro Capone, Francesco Messina, Carla Nisii, Antonino Di Caro
Summary: The study analyzed ceftazidime-avibactam-resistant KPC-producing Klebsiella pneumoniae strains collected from 31 patients in six hospitals in Rome, revealing mutations in KPC variants within the bla(KPC-3) gene and the presence of high-risk clones (ST512, 101, and 307). The findings highlight concerns over the potential selection of a multidrug-resistant phenotype in strains showing resistance to both ceftazidime-avibactam and carbapenems.
CLINICAL MICROBIOLOGY AND INFECTION
(2021)
Article
Microbiology
Yuchen Wu, Xuemei Yang, Congcong Liu, Yanyan Zhang, Yan Chu Cheung, Edward Wai Chi Chan, Sheng Chen, Rong Zhang
Summary: A new variant of Klebsiella pneumoniae carbapenemase (KPC-93) was identified in clinical isolates, causing resistance to ceftazidime-avibactam. The study highlights the potential risk of bla(KPC) gene mutations associated with ceftazidime-avibactam exposure over a short period of time.
MICROBIOLOGY SPECTRUM
(2022)
Article
Microbiology
Kalyani Borde, M. A. Kareem, Ratna Mani Sharma, S. Manick Dass, Vedantham Ravi, Dilip Mathai
Summary: This study aims to assess the in vitro susceptibility of clinical isolates of meropenem-resistant Klebsiella pneumoniae to the novel siderophore drug cefiderocol. The baseline resistance rates against cefiderocol are higher than previously published studies, with MIC50 and MIC90 at 2 and 8 mu g/mL, respectively.
MICROBIOLOGY SPECTRUM
(2023)
Article
Infectious Diseases
Gabriel Mendes, Joao F. Ramalho, Ana Bruschy-Fonseca, Luis Lito, Aida Duarte, Jose Melo-Cristino, Catia Caneiras
Summary: This article reports the molecular characterization of the first hypervirulent CZA-resistant ST13 KPC-70-producing K. pneumoniae strain in Portugal. The emergence of CZA-resistant strains might pose a serious threat to public health and suggests an urgent need for enhanced clinical awareness and epidemiologic surveillance.
Article
Infectious Diseases
Benjamin Davido, Anne-Claude Cremieux, Isabelle Vaugier, Laure Gatin, Latifa Noussair, Laurent Massias, Frederic Laurent, Azzam Saleh-Mghir
Summary: This study evaluated the efficacy of ceftazidime-avibactam (CAZ-AVI), a novel beta-lactam-beta-lactamase inhibitor, in combination with different antibiotics for the treatment of carbapenemase-producing Enterobacterales (CPE) bone infections. The results demonstrated that the combination of CAZ-AVI with colistin or gentamicin significantly reduced bacterial counts in the bone, achieving a bactericidal effect. CAZ-AVI plus gentamicin was found to be the most effective combination therapy.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2023)
Review
Infectious Diseases
Angela Cano, Julia Guzman-Puche, Manuel Garcia-Gutierrez, Juan Jose Caston, Irene Gracia-Ahufinger, Elena Perez-Nadales, Manuel Recio, Alejandra M. Natera, Eduardo Marfil-Perez, Luis Martinez-Martinez, Julian Torre-Cisneros
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE
(2020)
Article
Infectious Diseases
Juan Jose Caston, Marina Gallo, Manuel Garcia, Angela Cano, Antonio Escribano, Isabel Machuca, Irene Gracia-Aufinger, Julia Guzman-Puche, Elena Perez-Nadales, M. Recio, Monserrat Munoz, Luis Martinez-Martinez, Julian Torre-Cisneros
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2020)
Article
Infectious Diseases
Adolfo de Salazar, Antonio Aguilera, Rocio Trastoy, Ana Fuentes, Juan Carlos Alados, Manuel Causse, Juan Carlos Galan, Antonio Moreno, Matilde Trigo, Mercedes Perez-Ruiz, Carolina Roldan, Maria Jose Pena, Samuel Bernal, Esther Serrano-Conde, Gema Barbeito, Eva Torres, Cristina Riazzo, Jose Luis Cortes-Cuevas, Natalia Chueca, Amparo Coira, Juan Manuel Sanchez-Calvo, Eduardo Marfil, Federico Becerra, Maria Jose Gude, Angeles Pallares, Maria Luisa Perez Del Molino, Federico Garcia
CLINICAL MICROBIOLOGY AND INFECTION
(2020)
Article
Infectious Diseases
Doaa Gamal, Pilar Egea, Cristina Elias, Marta Fernandez-Martinez, Manuel Causse, Elena Perez-Nadales, Dalia Salem, Nevine Fam, Manal Diab, Aisha Abu Aitta, Inas El-Defrawy, Luis Martinez-Martinez
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2020)
Article
Infectious Diseases
Julia Guzman-Puche, Rocio Tejero-Garcia, Pilar Villalon, Silvia Pino-Rosa, Luis Martinez-Martinez
Summary: This study characterizes Streptococcus pyogenes isolates with a mucoid phenotype and specific toxin and genotype profiles during circulation. The main clinical manifestation is pharyngotonsillitis, with some cases progressing to scarlet fever.
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA
(2022)
Article
Infectious Diseases
Julia Guzman-Puche, Rim Jenayeh, Maria Perez-Vazquez, Manuel-Causse, Ferjani Asma, Boukadida Jalel, Jesus Oteo-Iglesias, Luis Martinez-Martinez
Summary: This study aimed to characterize OXA-48-producing Klebsiella oxytoca isolates causing an outbreak in a Tunisian hospital. The isolates were all positive for OXA-48 and negative for ESBL, carrying the bla(OXA-48) gene on a ca.63 kb IncL plasmid and belonging to the new ST220. These findings suggest challenges in detecting OXA-48 and a risk of overlooked production in K. oxytoca, potentially contributing to its hidden spread.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE
(2021)
Article
Microbiology
Eva Gato, Ahalieyah Anantharajah, Manuel J. Arroyo, Maria Jose Artacho, Juan de Dios Caballero, Ana Candela, Katerina Chudejova, Ignacio Pedro Constanso, Cristina Elias, Javier Fernandez, Jesus Jimenez, Pilar Lumbreras, Gema Mendez, Xavier Mulet, Patricia Perez-Palacios, Belen Rodriguez-Sanchez, Rafael Canton, Jaroslav Hrabak, Luis Mancera, Luis Martinez-Martinez, Antonio Oliver, Alvaro Pascual, Alexia Verroken, German Bou, Marina Oviano
Summary: In this study, the performance of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) for rapid detection of carbapenemase activity in Enterobacterales was evaluated. The method demonstrated high sensitivity and specificity, with an overall agreement rate of 92.5% relative to the reference standard. Results were obtained within 60 minutes and accuracy ranged from 83.3% to 100% among different centers. MALDI-TOF MS proves to be an outstanding tool for rapid detection of carbapenemase activity in clinical microbiology laboratories.
FRONTIERS IN MICROBIOLOGY
(2022)
Article
Infectious Diseases
Elena Perez-Nadales, Alejandra M. Natera, Manuel Recio-Rufian, Julia Guzman-Puche, Angela Cano, Azahara Frutos-Adame, Juan Jose Caston, Cristina Elias-Lopez, Manuel Romero-Saldana, Lorena Lopez-Cerero, Luis Martinez-Martinez, Julian Torre-Cisneros
Summary: This study developed a real-time quantitative PCR method to monitor the extent of intestinal colonisation by KPC-producing Klebsiella pneumoniae in colonised patients receiving selective digestive decontamination. The study found that the intestinal load of KPC-Kp decreased rapidly during SDD, but the persistent eradication rate was low after SDD.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE
(2022)
Article
Infectious Diseases
Eduardo Marfil, Pilar Ruiz, Luis Martinez-Martinez, Manuel Causse
Summary: This study compared the in vitro activity and minimal inhibitory concentration (MIC) distributions of tedizolid and linezolid against Mycobacterium avium complex (MAC) strains. The results showed that tedizolid exhibited higher in vitro activity against MAC isolates compared to linezolid.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE
(2022)
Article
Microbiology
Elena Perez-Nadales, Alejandra M. Natera, Manuel Recio-Rufian, Julia Guzman-Puche, Juan Antonio Marin-Sanz, Carlos Martin-Perez, Angela Cano, Juan Jose Caston, Cristina Elias-Lopez, Isabel Machuca, Belen Gutierrez-Gutierrez, Luis Martinez-Martinez, Julian Torre-Cisneros
Summary: Increased relative bacterial load of KPC-producing Klebsiella pneumoniae within the intestinal microbiota is associated with KPC-KP bacteremia. Giannella Risk Score predicts the development of all-site KPC-KP infection. KPC-KP relative intestinal load is independently associated with all-cause mortality in our clinical setting.
MICROBIOLOGY SPECTRUM
(2022)
Review
Infectious Diseases
Allison M. Hitchcock, Wesley D. Kufel, Keri A. Mastro Dwyer, Eric F. Sidman
Summary: Lenacapavir is a novel HIV-1 treatment option for patients with multidrug-resistant (MDR) HIV-1 infection. It has a favorable pharmacokinetic profile and has shown good tolerability and efficacy in clinical trials.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2024)
Article
Infectious Diseases
Roberta Gagliardini, Alessandro Tavelli, Stefano Rusconi, Sergio Lo Caputo, Vincenzo Spagnuolo, Maria Mercedes Santoro, Andrea Costantini, Alessandra Vergori, Franco Maggiolo, Andrea Giacomelli, Giulia Burastero, Giordano Madeddu, Eugenia Quiros Roldan, Antonella d'Arminio Monforte, Andrea Antinori, Alessandro Cozzi-Lepri
Summary: This study evaluated multiple treatment failures to modern antiretroviral therapy in HIV-infected individuals and found that approximately 4% of them were difficult to treat. The difficult to treat group, compared to the non-difficult to treat group, was characterized by older age, higher prevalence of AIDS, lower CD4+ cell count, and higher risk of treatment failure.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2024)